APA (7th ed.) Citation

DePaoli, A. M., Higgins, L. S., Henry, R. R., Mantzoros, C., & Dunn, F. L. (2014). Can a Selective PPARγ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone? Diabetes care, 37(7), 1918-1923. https://doi.org/10.2337/dc13-2480

Chicago Style (17th ed.) Citation

DePaoli, Alex M., Linda S. Higgins, Robert R. Henry, Christos Mantzoros, and Fredrick L. Dunn. "Can a Selective PPARγ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone?" Diabetes Care 37, no. 7 (2014): 1918-1923. https://doi.org/10.2337/dc13-2480.

MLA (9th ed.) Citation

DePaoli, Alex M., et al. "Can a Selective PPARγ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone?" Diabetes Care, vol. 37, no. 7, 2014, pp. 1918-1923, https://doi.org/10.2337/dc13-2480.